The efficacy and safety of metronomic vinorelbine combined with anlotinib in HER2-negative advanced breast cancer: a prospective, single-arm clinical study
Translational Breast Cancer Research · 2026-04 · 7 · 13-13
DOI: 10.21037/tbcr-25-48 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Breast Cancer Research, 2026-04. Verfasst von Xinli Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Xi'an International Medical Center Hospital, Xi'an, China. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Xi'an International Medical Center Hospital, Xi'an, China.
Zitieren
APA
Wang, X., Yang, T., Zhang, J., Yang, J., Gong, R., Liu, S., & Xue, Y. (2026). The efficacy and safety of metronomic vinorelbine combined with anlotinib in HER2-negative advanced breast cancer: a prospective, single-arm clinical study. Translational Breast Cancer Research, 7, 13-13. https://doi.org/10.21037/tbcr-25-48
Vancouver
Wang X, Yang T, Zhang J, Yang J, Gong R, Liu S, et al. The efficacy and safety of metronomic vinorelbine combined with anlotinib in HER2-negative advanced breast cancer: a prospective, single-arm clinical study. Translational Breast Cancer Research. 2026;7:13-13. doi:10.21037/tbcr-25-48
BibTeX
@article{Wang2026,
author = {Wang, Xinli and Yang, Ting and Zhang, Junmei and Yang, Jin and Gong, Ruizhi and Liu, Shusong and Xue, Yan},
title = {The efficacy and safety of metronomic vinorelbine combined with anlotinib in HER2-negative advanced breast cancer: a prospective, single-arm clinical study},
journal = {Translational Breast Cancer Research},
year = {2026},
volume = {7},
pages = {13--13},
doi = {10.21037/tbcr-25-48}
}
EUVIMED